https://www.healthcaretribunefrance.com/article/914346495-abl-diagnostics-advances-ngs-for-cmv-resistance-monitoring-at-seimc-2026 Healthcare Tribune France en PressRelease 2026-05-28T06:00:00+00:00 ABL Diagnostics Advances NGS for CMV Resistance Monitoring at SEIMC 2026 https://www.healthcaretribunefrance.com/article/915644736-enterome-receives-u-s-fda-orphan-drug-designation-for-eo2463-oncomimics-to-treat-watch-and-wait-indolent-non-hodgkin-lymphoma Healthcare Tribune France en PressRelease 2026-05-28T06:00:00+00:00 Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma https://ml-eu.globenewswire.com/media/e04b919f-9b3c-4d80-af54-707d3fa48216/small/enterome-logo-png.png https://www.healthcaretribunefrance.com/article/915644821-new-late-breaking-data-reinforces-iqirvo-s-impact-on-alp-fatigue-and-pruritus-in-pbc Healthcare Tribune France en PressRelease 2026-05-28T05:30:00+00:00 New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg https://www.healthcaretribunefrance.com/article/915644843-de-nouvelles-donn-es-late-breaking-renforcent-l-impact-d-iqirvo-sur-l-alp-la-fatigue-et-le-prurit-dans-la-cbp Healthcare Tribune France en PressRelease 2026-05-28T05:30:00+00:00 De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP. https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ https://www.healthcaretribunefrance.com/article/915632102-press-release-sanofi-s-venglustat-accepted-for-priority-review-in-the-us-to-treat-type-3-gaucher-disease Healthcare Tribune France en PressRelease 2026-05-28T05:00:00+00:00 Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/915632125-communiqu-de-presse-le-venglustat-de-sanofi-a-t-accept-pour-un-examen-prioritaire-aux-tats-unis-afin-de-traiter-la-maladie-de-gaucher-de-type-3 Healthcare Tribune France en PressRelease 2026-05-28T05:00:00+00:00 Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3   https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/915378522-abl-diagnostics-secures-new-global-tenders-and-continues-to-expand-distribution-network Healthcare Tribune France en PressRelease 2026-05-27T16:00:00+00:00 ABL Diagnostics Secures New Global Tenders and Continues to Expand Distribution Network https://www.healthcaretribunefrance.com/article/914386672-naqi-logix-joins-lenovo-innovation-accelerator-at-beyond-expo-at-macao Healthcare Tribune France en PressRelease 2026-05-26T11:15:00+00:00 Naqi Logix Joins Lenovo Innovation Accelerator at BEYOND Expo at Macao https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/21095661-naqi-logix-logo-1366x421.png https://www.healthcaretribunefrance.com/article/915249308-inventiva-reports-2026-first-quarter-financial-information Healthcare Tribune France en PressRelease 2026-05-26T20:00:00+00:00 Inventiva Reports 2026 First Quarter Financial Information¹ https://ml-eu.globenewswire.com/media/4e957060-eef5-4c1b-81e6-73683a4daa1e/small/inventiva-logo-1200x630-png.png https://www.healthcaretribunefrance.com/article/915249314-inventiva-publie-ses-informations-financi-res-du-premier-trimestre-2026 Healthcare Tribune France en PressRelease 2026-05-26T20:00:00+00:00 Inventiva publie ses informations financières du premier trimestre 2026¹ https://ml-eu.globenewswire.com/media/4e957060-eef5-4c1b-81e6-73683a4daa1e/small/